Microbial Genome Editing Platform

Microbial Genome Editing Platform

GeneRulor gene editing as its core technology, supported by a robust "One-Stop Gene Editing Platform" and scientific service system, to deliver comprehensive microbial genome modification solutions for the fields of synthetic biology, innovative biologics, and green biomanufacturing. This platform focuses on four core modules—Bacteria, Fungi, Algae, and Phage—capitalizing on a rich toolkit of foundational technologies and extensive experience in complex genome manipulation. We provide efficient, precise, and customizable services for the construction and optimization of microbial chassis cells for research institutions, biopharmaceutical companies, and industrial manufacturers.

Eight Core Service Modules

1. Bacterial Genome Editing

Supports fundamental research, industrial production, and live biotherapeutic product (LBP) development by providing efficient, targeted genomic modifications for both model and non-model bacterial strains.

Service Scope: Escherichia coli, Lactic Acid Bacteria, Bacillus subtilis, Pseudomonas, and various other Gram-negative and Gram-positive bacteria.

Technical Capabilities: Utilizing mature CRISPR-Cas systems and homologous recombination technologies to achieve single/multi-fragment knockout, precise large-fragment knock-in, point mutations, promoter replacement, and metabolic pathway reconstruction (e.g., targeted regulation of specific amino acid metabolism genes).

Application Scenarios: Construction of high-performance industrial chassis cells, development of engineered probiotics, high-level expression of recombinant proteins and antibodies.

2. Phage Genome Editing

Phage therapy and precision delivery are crucial directions for tackling drug-resistant bacteria and advancing novel gene therapies. We possess a leading phage engineering platform.

Service Scope: De novo synthesis and targeted modification of virulent and temperate bacteriophages.

Technical Capabilities: Scarless phage genome editing, precise expansion of host range, knockout of virulence/integrase genes, and construction of engineered phages armed with CRISPR systems for efficient delivery of specific payloads.

Application Scenarios: R&D of novel antimicrobials, precise editing of gut/environmental microbiomes, control of agricultural pathogens.

3. Fungal Genome Editing

Overcoming barriers in fungal genetic manipulation to accelerate the discovery and scaled production of high-value-added products.

Service Scope: Conventional yeasts (e.g., Saccharomyces cerevisiae, Pichia pastoris) and complex filamentous fungi (e.g., Aspergillus, Trichoderma).

Technical Capabilities: Sequential editing of multiple genomic regions, removal of resistance markers, integration of high-copy expression vectors, and activation of secondary metabolite gene clusters.

Application Scenarios: Discovery of natural products, development of novel enzyme preparations, biosynthesis of food and functional ingredients.

4. Algal Genome Editing

Providing superior photosynthetic chassis cells for carbon neutrality and green biomanufacturing.

Service Scope: Common industrial microalgae such as Chlamydomonas reinhardtii and Nannochloropsis.

Technical Capabilities: Establishing high-efficiency transformation systems that overcome cell wall barriers, achieving stable expression of exogenous genes, and directed optimization of lipid/pigment metabolic pathways.

Application Scenarios: Biofuel development, industrial production of high-value nutrients (e.g., PUFAs, astaxanthin).

5. Engineered Strain Construction

Offering full-cycle, customized services from conceptual design to engineered strain delivery, catering to the forefront of LBP development and synthetic biology.

Service Scope: Pharmaceutical-grade probiotics (e.g., various lactic acid bacteria, bifidobacteria), chassis E. coli, and specialized industrial strains.

Technical Capabilities: Multi-gene editing and fine-tuned regulation within complex genetic backgrounds. Enables deep reconstruction of specific metabolic pathways and stable, controllable expression of exogenous functional proteins in complex microenvironments like the gut.

Application Scenarios: Development of targeted microbiome therapies, construction of novel oral live bacterial vaccines, improvement of high-throughput fermentation industrial strains.

Compliance Enablement: Completed engineered strains can be seamlessly connected to GeneRulor Medical's safety assessment platform for exogenous gene safety analysis and pharmaceutical characterization, facilitating a direct path to IND application.

6. Phage Library Construction & Screening

Providing a highly competitive high-throughput phage screening platform to empower innovative biologic discovery and precise microbiome regulation.

Service Scope: Construction of natural phage libraries, phage display libraries (peptide/antibody display), and high-capacity engineered phage libraries.

Technical Capabilities: Capable of constructing ultra-large libraries (tens of billions of clones). Supports targeted modification of library phages, e.g., building engineered phage libraries armed with CRISPR systems for specific pathogen killing and efficient eradication of resistance genes.

Application Scenarios: Screening of fully human monoclonal antibodies, discovery of novel antimicrobial peptides, rapid matching for personalized phage therapy, and development of targeted delivery vectors.

7. Bacterial Transposon Mutagenesis Library Construction

Providing high-throughput, systematic foundational tools for microbial functional genomics research and novel drug target discovery.

Service Scope: Construction of genome-wide mutagenesis libraries (e.g., Tn5, Mariner) for various pathogenic bacteria, environmental microbes, and industrial strains.

Technical Capabilities: Achieves high-density, high-randomness insertion mutagenesis at the genomic level. Combined with high-throughput sequencing for precise insertion site mapping, enabling the construction of ultra-large mutant libraries.

Application Scenarios: Identification of bacterial essential genes, high-throughput mining of antibiotic resistance mechanisms and virulence factors, elucidation of host-pathogen interaction mechanisms.

8. Off-the-Shelf Microbial Gene Editing Plasmids

Providing validated, "out-of-the-box" gene editing tools for researchers and early-stage R&D teams to accelerate innovation.

Product Range: Includes CRISPR-Cas expression vectors, homologous recombination template plasmids, temperature-sensitive plasmids, and various promoter/fluorescent tag reporter plasmids for common model microorganisms (e.g., E. coli, lactic acid bacteria, yeast).

Product Advantages: All stock plasmids undergo rigorous sequencing verification and functional activity testing, ensuring high purity and low endotoxin levels. Designed with modularity for easy downstream cloning and part replacement.

Application Scenarios: Empowers research teams to rapidly conduct proof-of-concept studies, significantly reducing preliminary tool preparation time. Provides robust tool support for pre-experimental data collection for national/provincial grant applications and the swift drafting and filing of core technology patents.

Our Core Advantages

Full-Chain Technological Empowerment: We master multiple independently optimized CRISPR gene editing toolkits, overcoming editing challenges in "non-model microorganisms" with low transformation efficiency and complex genetic backgrounds, achieving scarless editing at the whole-genome level.

Seamless Linkage to Safety Assessment: Leveraging GeneRulor Medical's powerful off-target detection and molecular diagnostics system, engineered and modified gene-edited/probiotic strains can directly undergo whole-genome sequencing, exogenous gene safety analysis, and product residue testing, accelerating the compliance process.

Authoritative Quality and Hardware Systems: Operating within the company's 3000 m² GMP R&D laboratory and production facilities, adhering to both ISO9001 and CNAS certification standards. This ensures the genetic stability, purity, and quality of delivered strains meet industrial and clinical-grade requirements.